Cite
HARVARD Citation
Csiki, I. et al. (n.d.). 195TiP A first-in-human, phase I a/b dose escalation and expansion study to evaluate RBS2418 as monotherapy and in combination with pembrolizumab in subjects with advanced unresectable, recurrent or metastatic tumors. Immuno-oncology technology. p. . [Online].